More from Claudia Christian on the Sinclair Method

Link to Online Radio show about the Sinclair Method with Claudia Christian-

The Sinclair Method

Over the past few months I have read quite a lot about the Sinclair method for beating alcohol addiction, and have started a category on the blog that includes pieces from around the web about this method. As I have used abstinence to ensure sobriety for most of the last decade I cannot test this method, but am happy for people who do make use of this solution to do so. Claudia Christian wrote this for the site and Joanna from Cthreeeurope wrote this piece

I think that the Sinclair method could help so many people who have problems moderating, yet who cannot abstain on their own. Many people with addictions simply cannot improve much using some of the traditional methods, so this solution is badly needed. Here is a link to an online radio show that features Claudia Christian giving a really good explanation of how the Sinclair method can help people. She also mentions her great film called “One Little Pill”, which I talked about here and would recommend that you watch if you wish to find out more about this solution. Here is the trailer for the film.

Bloomberg Piece about Sinclair Method Drugs:

I glad to see that mainstream sources are picking up the fact that there are alternatives to traditional 12 step solutions, which may well be the answer for those, who are not motivated by the spiritual or religious parts of the AA program. The Sinclair Method may hopefully become known to more people. If people start to demand this solution then treatment centers and health services will have to modify their approach, to include a wider range of solutions. At the moment very few people are hearing about these methods which limits their effectiveness.

Here is a quote from the piece

Drugs to treat alcoholism can gain approval by proving patients using them no longer drink heavily, the Food and Drug Administration clarified Wednesday. The agency released draft guidelines for pharmaceutical companies wanting to develop alcoholism treatments that make clear that sobriety doesn’t have to be the main goal.

“The abstinence-based endpoints have often been considered an unattainable threshold in the clinical trial setting, and may be considered a hindrance to clinical development for drugs to treat alcoholism,” Eric Pahon, an FDA spokesman, said in an e-mail.

Clinical trials of the three drugs that are FDA-approved and sold for alcoholism focused on sobriety, and most required patients to be abstinent to start the studies, Pahon said. The National Institute on Alcohol Abuse and Alcoholism has said current medications are effective for some but that more treatments are needed for the broader population.

“While total abstinence from alcohol is desirable, reducing heavy drinking to within ‘low-risk’ daily limits presents an alternative goal in drug development so more treatments may be developed,” Pahon said.

Industry, researchers and addiction and recovery groups can comment on the proposal for 60 days.

Current Drugs

The drugs sold for alcoholism are: naltrexone, which limits the release of pleasure-inducing dopamine caused by alcohol; acamprosate, which can be used by those who have quit drinking to stay sober; and disulfiram, known as Antabuse, which creates unpleasant side effects in people who drink.

Alcoholism is identified as continued drinking despite physical and psychosocial consequences, according to the FDA proposal. Ultimately, an alcoholism drug should improve those consequences, which can be done through sobriety or a reduction in the use of alcohol, the agency said.

The NIAAA defines heavy drinking as a man consuming more than four standard drinks in a day or a woman taking more than three. A standard drink in the U.S. contains 14 grams of alcohol, which could be in the form of a shot of hard liquor, a 12-ounce bottle of beer or a 5-ounce glass of wine.

Selincro, made by H. Lundbeck A/S and Biotie Therapies Oyj, is the first and only drug approved in the European Union for reducing alcohol use, according to Bloomberg Intelligence analyst Grace Guo.

Arbaclofen from Reckitt Benckiser Group Plc and XenoPort Inc., TKM-ALDH2 from Tekmira Pharmaceuticals Corp. and Alnylam Pharmaceuticals Inc. and ADX71441 from Addex Therapeutics Ltd. are in early development to treat alcohol-use disorder, Guo said.

The NIAAA said in September it would start a clinical trial in the first half of this year on Santa Clara, California-based XenoPort’s restless-leg syndrome medicine Horizant as a treatment for alcohol use disorder.


Some extra links on the Sinclair Method:




Leave a Reply

You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>